US Patent

US9925157 — Enterically coated cysteamine, cystamine and derivatives thereof

Method of Use · Assigned to University of California San Diego UCSD · Expires 2027-01-26 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects enterically coated oral formulations of cysteamine, cystamine, and their derivatives for treating cystinosis and neurodegenerative diseases and disorders.

USPTO Abstract

The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

Drugs covered by this patent

cysteamine-bitartrate (CYSTEAMINE BITARTRATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1399`	—	cysteamine-bitartrate
`U-1399`	—	cysteamine-bitartrate
`U-1399`	—	cysteamine-bitartrate
`U-1399`	—	cysteamine-bitartrate

Patent Metadata

Patent number: US9925157
Jurisdiction: US
Classification: Method of Use
Expires: 2027-01-26
Drug substance claim: No
Drug product claim: Yes
Assignee: University of California San Diego UCSD
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.